California Pacific Medical Center, Research Institute, San Francisco, CA 94107, USA.
Breast Cancer Res Treat. 2011 Aug;129(1):37-47. doi: 10.1007/s10549-010-1177-4. Epub 2010 Sep 22.
Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxic therapies are urgently required. Id-1, an inhibitor of basic helix-loop-helix transcription factors, has recently been shown to be a key regulator of the metastatic potential of breast and additional cancers. We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, down-regulated Id-1 gene expression in aggressive human breast cancer cells in culture. Using cell proliferation and invasion assays, cell flow cytometry to examine cell cycle and the formation of reactive oxygen species, and Western analysis, we determined pathways leading to the down-regulation of Id-1 expression by CBD and consequently to the inhibition of the proliferative and invasive phenotype of human breast cancer cells. Then, using the mouse 4T1 mammary tumor cell line and the ranksum test, two different syngeneic models of tumor metastasis to the lungs were chosen to determine whether treatment with CBD would reduce metastasis in vivo. We show that CBD inhibits human breast cancer cell proliferation and invasion through differential modulation of the extracellular signal-regulated kinase (ERK) and reactive oxygen species (ROS) pathways, and that both pathways lead to down-regulation of Id-1 expression. Moreover, we demonstrate that CBD up-regulates the pro-differentiation factor, Id-2. Using immune competent mice, we then show that treatment with CBD significantly reduces primary tumor mass as well as the size and number of lung metastatic foci in two models of metastasis. Our data demonstrate the efficacy of CBD in pre-clinical models of breast cancer. The results have the potential to lead to the development of novel non-toxic compounds for the treatment of breast cancer metastasis, and the information gained from these experiments broaden our knowledge of both Id-1 and cannabinoid biology as it pertains to cancer progression.
侵袭和转移是癌症进展过程中的最后也是致命的步骤。临床上,对于侵袭性和转移性乳腺癌仍然缺乏有效的治疗方法。因此,迫切需要有效的、靶向的、非毒性的治疗方法。Id-1 是碱性螺旋-环-螺旋转录因子的抑制剂,最近被证明是调节乳腺癌和其他癌症转移潜能的关键调控因子。我们之前的研究表明,大麻素(CBD),一种毒性较低的大麻素,在培养中的侵袭性人乳腺癌细胞中下调 Id-1 基因的表达。通过细胞增殖和侵袭实验、细胞流式细胞术检测细胞周期和活性氧的形成以及 Western 分析,我们确定了 CBD 下调 Id-1 表达的途径,从而抑制了人乳腺癌细胞的增殖和侵袭表型。然后,我们使用小鼠 4T1 乳腺肿瘤细胞系和秩和检验,选择了两种不同的同源肿瘤转移到肺部的模型,以确定 CBD 治疗是否会减少体内转移。我们表明,CBD 通过不同调节细胞外信号调节激酶 (ERK) 和活性氧 (ROS) 途径抑制人乳腺癌细胞的增殖和侵袭,这两条途径都导致 Id-1 表达下调。此外,我们证明 CBD 上调了促分化因子 Id-2。然后,我们使用免疫功能正常的小鼠,证明 CBD 治疗显著降低了两种转移模型中的原发性肿瘤质量以及肺部转移灶的大小和数量。我们的数据证明了 CBD 在乳腺癌临床前模型中的疗效。这些结果有可能导致开发用于治疗乳腺癌转移的新型非毒性化合物,并且从这些实验中获得的信息拓宽了我们对 Id-1 和大麻素生物学的认识,这些知识与癌症进展有关。